Cendakimab
- Generic Name
- Cendakimab
- Drug Type
- Biotech
- Unique Ingredient Identifier
- O8R9U9ZUVN
- Background
Cendakimab is a recombinant humanized anti-interleukin 13 (IL-13) monoclonal antibody.
A Study to Evaluate the Safety and Tolerability of Cendakimab in Chinese Healthy Participants
- First Posted Date
- 2022-12-06
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 25
- Registration Number
- NCT05638282
- Locations
- 🇨🇳
Local Institution - 0001, Guangzhou, Guangdong, China
A Study to Evaluate the Drug Levels of Cendakimab Delivered Subcutaneously in Healthy Participants
- First Posted Date
- 2022-04-20
- Last Posted Date
- 2023-02-10
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 104
- Registration Number
- NCT05337345
- Locations
- 🇺🇸
Anaheim Clinical Trials Llc, Anaheim, California, United States
A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Japanese Participants With Eosinophilic Gastroenteritis
- Conditions
- Eosinophilic Gastroenteritis
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-01-31
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Celgene
- Target Recruit Count
- 48
- Registration Number
- NCT05214768
- Locations
- 🇯🇵
Local Institution - 002, Osaka, Japan
🇯🇵Local Institution - 022, Himeji-shi, Hyogo, Japan
🇯🇵Local Institution - 009, Nishinomiya, Hyogo, Japan
A Study Evaluating Potential Disease-Mediated Drug-Drug Interaction in Adult Participants With Active Eosinophilic Esophagitis Receiving Cendakimab
- First Posted Date
- 2022-01-03
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Celgene
- Target Recruit Count
- 16
- Registration Number
- NCT05175352
- Locations
- 🇺🇸
Local Institution - 021, Plantation, Florida, United States
🇺🇸Local Institution - 012, Columbus, Ohio, United States
🇺🇸Local Institution - 001, Los Angeles, California, United States
Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis
- First Posted Date
- 2021-08-05
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Celgene
- Target Recruit Count
- 259
- Registration Number
- NCT04991935
- Locations
- 🇺🇸
Local Institution - 082, Phoenix, Arizona, United States
🇺🇸Local Institution - 041, Scottsdale, Arizona, United States
🇺🇸Local Institution - 029, Tucson, Arizona, United States
A Study to Evaluate Safety and Effectiveness of Cendakimab (CC-93538) in Participants With Moderate to Severe Atopic Dermatitis
- First Posted Date
- 2021-03-16
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- Celgene
- Target Recruit Count
- 221
- Registration Number
- NCT04800315
- Locations
- 🇺🇸
Local Institution - 125, Silver Spring, Maryland, United States
🇨🇦Dr. Chih-ho Hong Medical Inc., Surrey, British Columbia, Canada
🇨🇦Local Institution - 213, Edmonton, Alberta, Canada
A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis
- First Posted Date
- 2021-02-15
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Celgene
- Target Recruit Count
- 430
- Registration Number
- NCT04753697
- Locations
- 🇺🇸
Local Institution - 092, Denver, Colorado, United States
🇺🇸Local Institution - 170, Littleton, Colorado, United States
🇺🇸Local Institution - 046, Florence, Kentucky, United States
Study to Evaluate the Pharmacokinetic Comparability of CC-93538 From Two Different Drug Concentrations in Healthy Adult Subjects
- First Posted Date
- 2020-05-04
- Last Posted Date
- 2021-09-28
- Lead Sponsor
- Celgene
- Target Recruit Count
- 52
- Registration Number
- NCT04373187
- Locations
- 🇺🇸
PPD Phase 1 Clinic, Austin, Texas, United States
Japanese Pharmacokinetic Bridging Study for CC-93538
- First Posted Date
- 2019-09-19
- Last Posted Date
- 2020-08-24
- Lead Sponsor
- Celgene
- Target Recruit Count
- 48
- Registration Number
- NCT04096105
- Locations
- 🇺🇸
Anaheim Clinical Trials, Anaheim, California, United States
Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis
- First Posted Date
- 2014-03-28
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- Celgene
- Target Recruit Count
- 100
- Registration Number
- NCT02098473
- Locations
- 🇺🇸
West Michigan Clinical Research Center Gastroenterology Associates of Western Michigan, Wyoming, Michigan, United States
🇺🇸Metropolitan Gastroenterology Group Chevy Chase Clinical Research, Chevy Chase, Maryland, United States
🇺🇸GI Associates and Endoscopy Center-GI Clinical Research Department, Flowood, Mississippi, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.